E
86.92
-0.13 (-0.16%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bullish | - |
Stockmoo Score
-0.3
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (Truist Securities, 26.56%) | Buy |
| Median | 104.50 (20.23%) | |
| Low | 91.00 (Evercore ISI Group, 4.70%) | Hold |
| Average | 103.00 (18.51%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 88.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 16 Jul 2024 | 110.00 (26.56%) | Buy | 87.73 |
| Citigroup | 10 Jul 2024 | 106.00 (21.96%) | Buy | 93.78 |
| 22 May 2024 | 105.00 (20.81%) | Buy | 90.21 | |
| Evercore ISI Group | 02 Jul 2024 | 91.00 (4.70%) | Hold | 91.23 |
| Goldman Sachs | 30 May 2024 | 107.00 (23.11%) | Buy | 87.89 |
| Deutsche Bank | 14 May 2024 | 103.00 (18.51%) | Buy | 86.46 |
| Barclays | 07 May 2024 | 101.00 (16.21%) | Buy | 85.84 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Jul 2024 | Announcement | Edwards Lifesciences Reports Second Quarter Results |
| 24 Jul 2024 | Announcement | Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix |
| 17 Jul 2024 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024 |
| 15 Jul 2024 | Announcement | Edwards Lifesciences to Acquire Innovalve |
| 05 Jun 2024 | Announcement | Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR |
| 03 Jun 2024 | Announcement | Edwards Lifesciences to Sell Critical Care to BD |
| 03 Jun 2024 | Announcement | BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader |
| 08 May 2024 | Announcement | Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |